Deep re-opening in the first half of 2020 China Biopharmaceutical nearly 100 cases of financing.

Source: Medical Mission Hills ended in the first half of 2020.
according to incomplete statistics, china's biomedicine and technology fields in the past six months completed at least 97 financing, the overall more active.
we have seen a number of innovative biopharmaceutical companies at different stages of development receive considerable financial support.
this article will resume these financing cases, to see the first half of 2020 China's biopharmaceutical company financing mainly showed what bright spots? Highlight s1: Early financing accounts for about 42%, and Innovative Therapy Pilots has the largest number of early financing (A-plus rounds and before) of the 97 financing cases, accounting for 42% of the total.
angels have six, Pre-A rounds have 12 and A-rounds and A-plus have 23.
in terms of research and development, these companies cover many of the current cutting-edge technologies and innovative therapies, including gene therapy, cancer vaccines, mRNA drugs, cell therapy, early development of membrane protein targeting new drugs, the use of artificial intelligence to develop drugs, and more.
for example, Newforth is dedicated to the treatment of eye genetic diseases with gene therapy, microbes focus on mRNA personalized cancer vaccine, genetic disease mRNA drugs, etc. research and development, the agent Tai medicine, Wangshi wisdom, etc. is the use of artificial intelligence technology for drug development.
some of the new focus on new cell therapies, including Westlake Biomedicine, Junsay Biology and other companies.
, West Lake Biomedicine has developed a new personalized red blood cell treatment technology, that is, human intravenous blood and other sources of stem cells, targeted transformation into red blood cells carrying targeted drugs.
using this red blood cell therapy technology, the company has developed a variety of innovative treatments for major diseases such as cancer, infectious diseases, rare diseases, immunity and metabolism.
Junsay Is Focused on the development of new solid tumor cell therapies, including innovative tumor therapies based on tumor-immersed lymphocytes (TIL).
it is worth mentioning that a number of detection / medical examination field of new sharp also have the capital favor, their areas of concern include tumor liquid biopsy nanotechnology, single-molecule detection technology, pathogenic microbial detection, early diagnosis of tumors and so on.
the table below for some of the early financing cases. note
Note: This table is organized according to public information, for incomplete statistics, statistical period: 2020/1/1-2020/6/30, the content team mapping of the drug Ming Kant.
highlights: Kangfang Bio, Pharmaceutical Sinjuno and other companies to raise $100 million and above in our statistics of 97 financing cases, B-round F round financing has 29 cases, of which B-b-round cases accounted for 62% (18).
note, at least four of the companies that disclosed specific financing amounts (excluding uncertain amounts of financing, such as tens of millions of yuan, etc.) raised more than $100 million, including Kangfang Bio, Pharmaceutical Sinjuno, Jiahe Bio and Chongsheng Group.
: Completed a $163m round F financing in April, the company's last before it went public.
Kangfang Bio is committed to the development of innovative antibody therapy in the field of oncology, immunology and other therapeutic fields, and has established a product pipeline involving more than 20 drug development projects, including PD-1/CTLA-4 dual resistance, PD-1/VEGF dual resistance, IL-17 monotophosis, PCSK9 monotophosis and other drugs in the research.
the company was officially listed on the Hong Kong Stock Exchange on April 24, raising more than $300m.
drug Ming Juno: is a focus on the development, transformation and application of cell immunotherapy, in the clinical stage of innovative biopharmaceutical company, the company's leading products for the target CD19 CAR-T treatment products Ruikilensai injection (tentative, JWCAR029), the drug's listing application has recently been accepted by the State Drug Administration of China, adaptation for relapsing refractive lymphoma.
In June this year, the company completed a $100 million round B financing, which will be used to continue to promote clinical research of CAR-T therapy JWCAR029, further expand the research and development pipeline and commercialpreparation to support the launch of new products.
Jiahe Bio: an innovative biopharmaceutical company driven by research and development, with more than ten research products, 10 of which are in clinical development, including PD-1 monophonosis, HER2 monotophos, TNF-alpha antibodies, etc., covering oncology and other major diseases.
completed a $160 million round B financing in June.
it is worth mentioning that Jiahe Bio submitted its IPO application to the Hong Kong Stock Exchange on June 26.
Chongsheng Group: is a clinical phase of biopharmaceutical companies, currently has more than 10 new drug projects, including Claudin 18.2 humanized monoclonal antibodies, covering cancer, orthopaedics, kidney disease and other disease areas. in addition to the self-developed drugs, the
group obtained exclusive development licenses from Eli Lilly and Company in March 2019 for the exclusive development of the latter's entire orthopaedic innovative biopharmaceutical product line in Greater China.
the company completed a $100 million B-plus round of financing earlier this year.
the table below is some of the financing cases for rounds B and above. note
Note: This table is organized according to public information, for incomplete statistics, statistical period: 2020/1/1-2020/6/30, the content team mapping of the drug Ming Kant.
yuan and US dollar conversion sits at the July 14 exchange rate.
Highlights 3: 12 companies successfully IPO, HKEx/CSK as the preferred 2018, THE Hong Kong Stock Exchange and The SSE respectively reform, opening up a new path for financing For Chinese biotechnology enterprises.
April 2018, the Hong Kong Stock Exchange underwent its biggest listing reform in 25 years, opening its doors to biotech companies that do not yet have revenues.
the end of 2018, the Shanghai Stock Exchange began to set up a science and technology board and pilot registration system, focusing on encouraging companies in six major areas, such as biomedicine, to list on the board, and officially opened in July 2019, bringing new vitality to China's capital market and the medium- and long-term development of China's science and technology.
since the implementation of the new rules, the Hong Kong Stock Exchange and The XK board have become the preferred listing of many Chinese unprofitable biopharmaceutical companies, which was again confirmed in the financing cases in the first half of this year.
, according to public information, at least 12 Chinese biopharmaceutical companies successfully made IPOs in the first half of the year, seven of which chose to list on the Hong Kong Stock Exchange or Cotron Board (see table below).
, the company, which is listed on Cotron Board, recently said it would also plan to list on the Hong Kong Stock Exchange.
from the research and development field, these 12 companies, there are a number of tumor, autoimmune disease drugs, such as Kangfang Bio, Novartis Jianhua, Tianyi Bio, Zersin Pharmaceuticals and so on.
analyzing the companies' research and development pipelines, we found that their innovative technologies and treatments include bispecific antibodies, antibody coupling drugs, CAR-T cell therapy, monotoidal (CD47, PD-1), BTK inhibitors, FGFR inhibitors, vaccines, and more.
some of the products in the research have entered the listing declaration stage, such as Noshicheng Jianhua's BTK inhibitor Obitini, Zei Pharmaceutical's multikine inhibitor Donafini, Shenzhou cell recombinant human coagulation factor VIII and CD20 antibodies, Kangfang Bio and Zhengda Tianqing co-development of PD-1 monoantiapian monovirus and so on. note
Note: This table is organized according to public information, for incomplete statistics, statistical period: 2020/1/1-2020/6/30, the content team mapping of the drug Ming Kant.
highlights four: and Huang Pharma and other companies to obtain equity investment, strategic investment in addition to the above-mentioned financing cases, in the first half of the year, there are a number of biopharmaceutical companies completed equity investment, strategic investment.
, Hutchison Pharmaceuticals received a $100 million equity investment from Transatlantic Investments.
the company's focus on the development of cancer and autoimmune disease drugs, and its self-developed furanquine has been approved for the treatment of colorectal cancer in China.
, according to a recent press release from Hutchison Pharmaceuticals, the company currently has eight cancer-fighting drug candidates in development worldwide and has made significant progress in 2020, with two drugs, epinetrycinand sofaninib, having been granted three fast-track qualifications by the FDA.
at the same time, companies such as Legendary Creatures, which focus on cell immunotherapy development, and Sharpbio, which focus on human microbiome research, have received different amounts of strategic investment.
in addition, a number of companies, including Rongchang Bio, Hongsheng Pharmaceuticals, Ai Weixin, Kexing Zhongwei, Pumis, Unia Pharmaceuticals, etc., have also completed different amounts of unknown round financing.
(unknown wheel refers to the public information channels did not query the specific round and nature of these financings) to pay attention to the "Drug Mingkang" WeChat public number.